Medical devices, healthcare technology and the business of care
510(k) clearance · K253011

Catalyft PL Expandable Interbody System

MEDTRONIC SOFAMOR DANEK USA, INC. · Decision date Jul 17, 2026

FDA DECISIONK253011

What did the FDA decide?

FDA records K253011 as a 510(k) premarket notification, with a decision dated Jul 17, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Orthopedic
Decision date
Jul 17, 2026

FDA source record

Regulatory record facts

Identifier
K253011
Regulatory pathway
510(k) premarket notification
Product code
MAX
Decision code
SESE
Decision date
Jul 17, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Intervertebral Fusion Device With Bone Graft, Lumbar.

Product code
MAX
FDA device class
2

FDA decision timeline

  1. K253011 received

    Application receipt date recorded by FDA.

  2. K253011 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code MAX

Product / regulatory recordCompanyPathwayDecision dateSource
Solco Biomedical Company India Private Limited510(k) clearanceNov 6, 2026FDA
MEDTRONIC SOFAMOR DANEK USA, INC.510(k) clearanceOct 29, 2026FDA
Alphatec Spine, Inc.510(k) clearanceOct 21, 2026FDA
SCALA TLK261049
Spineart SA510(k) clearanceAug 20, 2026FDA
Life Spine, Inc.510(k) clearanceJul 28, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Sofamor DANEK USA, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
Memphis, TN

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records